Stock Track | Moderna Soars 5% in Pre-Market as FDA Approval of First mRNA Flu Vaccine Continues to Drive Gains

Stock Track

Aug 10

Moderna, Inc. (MRNA) surged 5.00% in pre-market trading on Monday, extending its recent rally as investor enthusiasm over the FDA approval of its seasonal influenza vaccine, mFLUSIVA, showed no signs of cooling.

The approval, which came earlier this month, marks a historic milestone as the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. mFLUSIVA is approved for adults aged 50 and above, and the company expects availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also under regulatory review in Australia, Canada, and Europe, further bolstering market confidence in Moderna's mRNA platform expansion and commercialization prospects.

The regulatory green light followed an earlier setback, making the approval a significant commercial victory for the biotech firm. While some analysts, such as Bank of America, have maintained cautious ratings, the broader market sentiment has turned increasingly positive on the stock's ability to diversify beyond its COVID-19 vaccine portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121159582"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121159582\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121159582?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 16:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121159582","market":"hk","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5% in Pre-Market as FDA Approval of First mRNA Flu Vaccine Continues to Drive Gains","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) surged 5.00% in pre-market trading on Monday, extending its recent rally as investor enthusiasm over the FDA approval of its seasonal influenza vaccine, mFLUSIVA, showed no signs of cooling.</p><p>The approval, which came earlier this month, marks a historic milestone as the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. mFLUSIVA is approved for adults aged 50 and above, and the company expects availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also under regulatory review in Australia, Canada, and Europe, further bolstering market confidence in Moderna's mRNA platform expansion and commercialization prospects.</p><p>The regulatory green light followed an earlier setback, making the approval a significant commercial victory for the biotech firm. While some analysts, such as Bank of America, have maintained cautious ratings, the broader market sentiment has turned increasingly positive on the stock's ability to diversify beyond its COVID-19 vaccine portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5% in Pre-Market as FDA Approval of First mRNA Flu Vaccine Continues to Drive Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5% in Pre-Market as FDA Approval of First mRNA Flu Vaccine Continues to Drive Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-10 16:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) surged 5.00% in pre-market trading on Monday, extending its recent rally as investor enthusiasm over the FDA approval of its seasonal influenza vaccine, mFLUSIVA, showed no signs of cooling.</p><p>The approval, which came earlier this month, marks a historic milestone as the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. mFLUSIVA is approved for adults aged 50 and above, and the company expects availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also under regulatory review in Australia, Canada, and Europe, further bolstering market confidence in Moderna's mRNA platform expansion and commercialization prospects.</p><p>The regulatory green light followed an earlier setback, making the approval a significant commercial victory for the biotech firm. While some analysts, such as Bank of America, have maintained cautious ratings, the broader market sentiment has turned increasingly positive on the stock's ability to diversify beyond its COVID-19 vaccine portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1121159582","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121159582","pubTimestamp":1786352065,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) surged 5.00% in pre-market trading on Monday, extending its recent rally as investor enthusiasm over the FDA approval of its seasonal influenza vaccine, mFLUSIVA, showed no signs...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票跟踪 | FDA 批准首款 mRNA 流感疫苗继续推动上涨，Moderna 盘前飙升 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) surged 5.00% in pre-market trading on Monday, extending its recent rally as investor enthusiasm over the FDA approval of its seasonal influenza vaccine, mFLUSIVA, showed no signs of cooling.The approval, which came earlier this month, marks a historic milestone as the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. mFLUSIVA is approved for adults aged 50 and above, and the company expects availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also under regulatory review in Australia, Canada, and Europe, further bolstering market confidence in Moderna's mRNA platform expansion and commercialization prospects.The regulatory green light followed an earlier setback, making the approval a significant commercial victory for the biotech firm. While some analysts, such as Bank of America, have maintained cautious ratings, the broader market sentiment has turned increasingly positive on the stock's ability to diversify beyond its COVID-19 vaccine portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}